125 related articles for article (PubMed ID: 26722761)
1. LOX1 inhibition with small molecules.
Gousiadou C; Kouskoumvekaki I
J Mol Graph Model; 2016 Jan; 63():99-109. PubMed ID: 26722761
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
3. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
Deniz U; Ozkirimli E; Ulgen KO
J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
[TBL] [Abstract][Full Text] [Related]
4. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
Ahmadi M; Nowroozi A; Shahlaei M
J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810
[TBL] [Abstract][Full Text] [Related]
5. Homology modeling of 5-lipoxygenase and hints for better inhibitor design.
Aparoy P; Reddy RN; Guruprasad L; Reddy MR; Reddanna P
J Comput Aided Mol Des; 2008 Sep; 22(9):611-9. PubMed ID: 18231862
[TBL] [Abstract][Full Text] [Related]
6. Binding sites and hydrophobic pockets in Human Thioredoxin 1 determined by normal mode analysis.
Philot EA; Perahia D; Braz AS; Costa MG; Scott LP
J Struct Biol; 2013 Nov; 184(2):293-300. PubMed ID: 24036282
[TBL] [Abstract][Full Text] [Related]
7. Probing conformational changes in lipoxygenases upon membrane binding: fine-tuning by the active site inhibitor ETYA.
Di Venere A; Nicolai E; Ivanov I; Dainese E; Adel S; Angelucci BC; Kuhn H; Maccarrone M; Mei G
Biochim Biophys Acta; 2014 Jan; 1841(1):1-10. PubMed ID: 24012824
[TBL] [Abstract][Full Text] [Related]
8. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
Meslamani J; Li J; Sutter J; Stevens A; Bertrand HO; Rognan D
J Chem Inf Model; 2012 Apr; 52(4):943-55. PubMed ID: 22480372
[TBL] [Abstract][Full Text] [Related]
9. Curcumin analogues as possible anti-proliferative & anti-inflammatory agents.
Katsori AM; Chatzopoulou M; Dimas K; Kontogiorgis C; Patsilinakos A; Trangas T; Hadjipavlou-Litina D
Eur J Med Chem; 2011 Jul; 46(7):2722-35. PubMed ID: 21514701
[TBL] [Abstract][Full Text] [Related]
10. Application of Docking Analysis in the Prediction and Biological Evaluation of the Lipoxygenase Inhibitory Action of Thiazolyl Derivatives of Mycophenolic Acid.
Tsolaki E; Eleftheriou P; Kartsev V; Geronikaki A; Saxena AK
Molecules; 2018 Jul; 23(7):. PubMed ID: 29970872
[TBL] [Abstract][Full Text] [Related]
11. Protein pharmacophore selection using hydration-site analysis.
Hu B; Lill MA
J Chem Inf Model; 2012 Apr; 52(4):1046-60. PubMed ID: 22397751
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of vegetative soybean lipoxygenase VLX-B and VLX-D, and comparisons with seed isoforms LOX-1 and LOX-3.
Youn B; Sellhorn GE; Mirchel RJ; Gaffney BJ; Grimes HD; Kang C
Proteins; 2006 Dec; 65(4):1008-20. PubMed ID: 17022084
[TBL] [Abstract][Full Text] [Related]
13. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
[TBL] [Abstract][Full Text] [Related]
14. Identification of Binding Mode and Prospective Structural Features of Novel Nef Protein Inhibitors as Potential Anti-HIV Drugs.
Moonsamy S; Bhakat S; Ramesh M; Soliman ME
Cell Biochem Biophys; 2017 Mar; 75(1):49-64. PubMed ID: 27981421
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A₂, cyclooxygenases, lipoxygenase and proinflammatory cytokines.
Bukhari SN; Lauro G; Jantan I; Bifulco G; Amjad MW
Bioorg Med Chem; 2014 Aug; 22(15):4151-61. PubMed ID: 24938495
[TBL] [Abstract][Full Text] [Related]
16. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
17. Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET-based screening, molecular docking and dynamics simulation.
Singh S; Awasthi M; Pandey VP; Dwivedi UN
J Biomol Struct Dyn; 2017 Feb; 35(3):657-668. PubMed ID: 26942689
[TBL] [Abstract][Full Text] [Related]
18. Structure of soybean lipoxygenase L3 and a comparison with its L1 isoenzyme.
Skrzypczak-Jankun E; Amzel LM; Kroa BA; Funk MO
Proteins; 1997 Sep; 29(1):15-31. PubMed ID: 9294864
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
[TBL] [Abstract][Full Text] [Related]
20. Molecular fields in ligand discovery.
Gane PJ; Chan AW
Methods Mol Biol; 2013; 1008():479-99. PubMed ID: 23729264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
